CAP, IASLC, and AMP Seek Public Comments on Revised Molecular Testing Guideline to Improve Lung Cancer Patient Selection and Targeted Therapies

International Lung Cancer Experts Seek Public Comments on Revised Molecular Testing Guideline to Improve Patient Selection and Targeted Therapies

"The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) announced today the open comment period for the revised evidence-based guideline, "Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors."

The open comment period begins today and will close on August 2, 2016. The online format provides an opportunity for public review of new draft recommendations for several key topics, as well as recommendation statements that have been reaffirmed since the initial guideline was jointly published online in April 2013 byArchives of Pathology & Laboratory Medicine, The Journal of Thoracic Oncology, and The Journal of Molecular Diagnostics."